New European study shows Zelmac* significantly improves IBS symptoms
Results from first, large, multinational study in Nordic countries published
Basel, 13 February 2004 - Zelmac® (tegaserod), a new treatment for irritable bowel syndrome (IBS) provides patients satisfying overall relief of symptoms, including abdominal pain and discomfort, bloating and constipation, according to a new study just published in the Scandinavian Journal of Gastroenterology.
* Zelmac is marketed under the trademark Zelnorm® (tegaserod maleate) in the US, Canada, Philippines and South Africa
Please see full press release under the following link:
